|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Although MET amplification-positive tumor is considered aggressive, our results suggest that it has a more favorable prognosis than amplification-negative cases in stage IV pulmonary adenocarcinoma with medical treatment.
|
31329925 |
2019 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High MET protein expression was detected in 25% (193/763), and was significantly more common in adenocarcinomas than squamous cell carcinoma (P<0.01).
|
31106127 |
2019 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Sanchez-Vega and colleagues prospectively demonstrate that both intra- and intertumoral differential expression of the receptor tyrosine kinases HER2, EGFR, and MET dictate sensitivity to the pan-HER inhibitor afatinib in a phase II trial of trastuzumab-refractory <i>HER2</i>-amplified gastroesophageal adenocarcinomas.
|
30737213 |
2019 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In the subgroup of adenocarcinoma and squamous cell carcinoma patients with stage IIA-IIIB disease, the prognostic impact of c-MET was significant in the univariate analysis (HR = 0.60, 95% CI: 0.43-0.83).
|
31200831 |
2019 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The MET gene had increased copy numbers in 9.88% of the NSCL adenocarcinoma patients; 3.49% of MET mutations in NSCL adenocarcinoma included 3 intron mutations.
|
28952227 |
2019 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The major histologic type was adenocarcinoma (66.8%). c-MET was overexpressed in 55.8% (87/156) and dominant in females as well as non-squamous histology.
|
29502124 |
2018 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A KIF5B-MET fusion variant in a patient with a mixed-type adenocarcinoma and sarcomatoid tumor was identified, and another case was found in a pulmonary sarcomatoid carcinoma patient.
|
30015159 |
2018 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We conducted an analysis of the effect of MET expression and MET genomic aberrations on the outcome of patients with advanced or metastatic pulmonary adenocarcinomas prospectively enrolled in an institutional precision oncology program.
|
29631966 |
2018 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MET exon 14 skipping and missense mutations were identified in two (11.1%) cases with adenocarcinoma histology.
|
29489023 |
2018 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Subgroup analyses suggest that high MET CNG is associated with a worse prognosis, especially in patients with adenocarcinoma and Asian populations.
|
29805710 |
2018 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
CUP adenocarcinomas and poorly differentiated carcinomas harboured the highest frequency of variants in genes involved in signal transduction pathways (e.g.MET, EGFR, HRAS, KRAS, and BRAF).
|
29973234 |
2018 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MET IHC+ was found in 23.8% of 2432 patients, significantly associated with female gender, small tumor size, and adenocarcinoma histology.
|
28838386 |
2017 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MET exon 14 alterations were enriched in PSC (12%) compared with non-PSC NSCLCs (∼3%) (p < 0.0001) and were more prevalent in PSC cases with an adenocarcinoma component.
|
28315738 |
2017 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
C-MET and phospho-MET overexpression occurred preferentially in ADCs and in areas involved in tumor progression, in support of the view that MET activation plays a role in the development of an invasive phenotype in NSCLC.
|
28098570 |
2017 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Although MET and HGF are commonly expressed in biliary tract cancers, their expression and gene copy number status and their association with KRAS mutations have not been investigated in pancreatobiliary-type ampullary adenocarcinomas (A-ACs), one of the aggressive periampullary cancers.
|
28214200 |
2017 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Samples from 447 GEC patients were analyzed for MET gene amplification (FISH) and Met protein expression (IHC and SRM).
|
27926778 |
2017 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
All (9/9) of the MET-mutated adenocarcinomas showed acinar predominant histology with associated lepidic patterns.
|
28285687 |
2017 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In univariate analyses, high cytoplasmic MET expression showed a significant negative prognostic effect in adenocarcinoma patients (p = 0.026).
|
28742836 |
2017 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The lung cancer subtypes share some genetic variations such as the dysfunction of tumor suppressor gene TP53, and also harbor specific variations of their own such as MET in ADC, FGFR1 and FGFR3 in SCC and MYC in SCLC.
|
27845189 |
2017 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET amplification was more frequent in advanced-stage disease and in the solid predominant subtype of adenocarcinoma.
|
28322191 |
2017 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MET exon 14 alterations, which result in increased MET protein levels due to disrupted ubiquitin-mediated degradation, occur at a prevalence of around 3% in adenocarcinomas and around 2% in other lung neoplasms, making them attractive targets for the treatment of lung cancer.
|
28024693 |
2017 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Based on our study findings, SC patients should be screened for MET exon 14 mutations in the same manner as adenocarcinoma patients.
|
28418914 |
2017 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MET exon 14 skipping occurs with an approximately 5% frequency in NSCLC and is seen in both squamous and adenocarcinoma histology.
|
27022036 |
2016 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The numbers of CD8(+) and programmed cell death-1(+) lymphocytes were higher in smokers (P = 0.012 and 0.016) and MET-expressing adenocarcinomas (P < 0.001).
|
26183759 |
2015 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Study of MET protein levels and MET gene copy number in 72 sinonasal intestinal-type adenocarcinomas.
|
24913906 |
2015 |